

1 **Deep skin dysbiosis in vitiligo patients: link with mitochondrial and immune changes**

2

3 **Authors:** Hanene Bziouche^{1*}, Kotryna Simonyté Sjödin^{2*}, Christina E West², Abdallah
4 Khemis³, Stéphane Rocchi¹, Thierry Passeron^{1,3 †§} and Meri K Tulic^{1 †§}

5

6 **Affiliations:**

7 ¹Université Côte d'Azur, INSERM U1065, Centre Méditerranéen de Médecine Moléculaire
8 (C3M), Nice, France

9 ² Department of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden

10 ³ Côte d'Azur University. Department of Dermatology, University Hospital of Nice, France

11

12 * These two authors contributed equally to this work, † equal senior-author contributions

13 § corresponding authors

14

15

16 § **Correspondences:**

17 Dr Meri K Tulic

18 INSERM U1065, C3M

19 150 route de Ginestiere 06200 Nice, France

20 Email: meri.tulic@unice.fr

21

22 Pr. Thierry Passeron

23 Department of Dermatology, Archet 2 Hospital.

24 150 route de Ginestiere 06200 Nice, France

25 Email: passeron@unice.fr

26

27

28

29

30 **Running Title:** Gut and skin dysbiosis in vitiligo

31

32

33

34 **ABSTRACT**

35 **Rationale:** Vitiligo is an autoimmune-disease characterized by patchy, white skin due to
36 melanocyte loss. Commensal cutaneous or gut dysbiosis have been linked to various
37 dermatological disorders. Here, we studied skin and gut microbiota of vitiligo patients
38 compared to healthy controls. **Methods:** We recruited 20 subjects and obtained swabs and
39 biopsies from lesional and non-lesional skin, stool and blood from each individual (total 100
40 samples). **Results:** We detected reduced richness and distribution of microbiota in stool of
41 vitiligo subjects compared to controls ($P<0.01$). Skin swabs had greater alpha-diversity than
42 skin biopsies ($P<0.001$), however only trends were seen between groups when examining
43 microbiota at the skin surface. This was in contrast to sampling deeper layers of skin from the
44 same patients which showed decreased richness and distribution of species ($P<0.01$) but
45 greater phylogenetic diversity ($P<0.01$) in lesional compared to non-lesional sites. Biopsy
46 microbiota from the lesional skin had distinct microbiota composition which was depleted of
47 protective *Bifidobacterium* and enriched in *Terenicutes*, *Streptococcus*, *Mycoplasma* and
48 mitochondrial DNA ($P<0.001$); the latter was linked with increased innate immunity and stress
49 markers in the blood of the same patients ($P<0.05$). **Conclusion:** These data describe vitiligo-
50 specific cutaneous and gut microbiota and, for the first time in humans, a link between
51 mitochondrial alteration, innate immunity and skin microbiota.

52

53 **Keywords:** skin dysbiosis, microbiota, vitiligo, immunity, melanocytes

54

55 INTRODUCTION

56 Vitiligo is characterized by an acquired loss of melanocytes in the skin and sometimes in the
57 hair follicles. It is now well demonstrated that CD8⁺ T cells attracted in the epidermis are
58 responsible for the melanocytic loss. Genome-wide association studies (GWAS) identified over
59 50 vitiligo susceptibility loci involved in melanogenesis and immunity in vitiligo patients [1].
60 However, these genetic studies and a delay in vitiligo age-of-onset over the past 30 years
61 emphasize the key role of environmental factors in triggering vitiligo [2]. We recently
62 demonstrated that vitiligo patients have an increased number of natural killer (NK) and innate
63 immune cells (ILC1) in their non-lesional skin and their blood, and that those innate cells have
64 a greater response to stress, producing higher amount of IFN γ leading to the production of
65 chemokine (C-X-C motif) ligand 9 (CXCL9), CXCL10 and CXCL11 by both keratinocytes and
66 melanocytes and to a CXCR3B-induced apoptosis in melanocytes [3]. We demonstrated that
67 these early events which lead to CD8⁺ T cell-mediated adaptative response against
68 melanocytes can be triggered by endogeneous or exogeneous stress, namely damage and
69 pattern-associated molecular patterns (DAMPs and PAMPs, respectively). Bacteria are among
70 the top producers of PAMPs and could participate in activation of the innate immune response
71 in vitiligo. Interestingly, gut dysbiosis has been reported in several auto-immune disorders.
72 Although less reported, skin dysbiosis is also observed in some dermatoses, such as acne,
73 psoriasis and atopic dermatitis [4-6]. Most of these studies assessed the superficial
74 microbiome using swabs. However, recent data emphasized the differences in the microbiome
75 between the surface and the deeper part of the skin using biopsy samples [7,8]. Surprisingly,
76 data on the microbiome in vitiligo patients remains sparse. To date, there exists only one study
77 suggesting dysbiosis in vitiligo skin [9], however the authors only assessed the superficial skin
78 microbiota using swabs and compared lesional to non-lesional vitiligo skin without including
79 healthy controls. A more recent study in a mouse model of vitiligo has shown that antibiotic-
80 induced depletion of *Bacteroides*-dominated population in the gut may induce depigmentation
81 in the skin suggesting a possible link between gut and skin compartments [10]. In the present

82 study, we compared for the first time, the microbiota of gut, superficial and deeper parts of
83 lesional and non-lesional skin of vitiligo patients and compared these results to sample and
84 site matched healthy controls. We found gut dysbiosis with a reduced *Bacteroides* population
85 in vitiligo patients. We also report marked differences of the microbiota using swabs and skin
86 biopsies. Finally, we report significant variation in microbiota diversity and quality in the deeper
87 regions of lesional vitiligo skin and these changes to be associated with mitochondrial damage
88 and changes in skin immunity.

89

90

91 RESULTS

92 *Vitiligo disease is associated with lower α -diversity and increased Firmicutes/Bacteroidetes*
93 *fraction in the gut*

94 First, we set out to examine if we could detect differences in microbial composition and diversity
95 in the gut of patients with vitiligo skin disease (n=10) compared to healthy controls (n=10).
96 Here we show lower gut microbial α -diversity in vitiligo patients compared to healthy controls
97 (for observed OTUs P=0.005; Shannon diversity index P=0.115; and Faith's Phylogenetic
98 Diversity H=5.851, P=0.006) (Figure 1A). β -diversity did not differ between the groups. We
99 found trends for higher bacterial relative abundance (RA) of *Firmicutes* (P=0.09) and lower
100 *Bacteroidetes* (P=0.08) in the stools of vitiligo subjects compared to healthy controls (Figure
101 1B and Supplementary Table 1) which is likely to be a result of reduced *Bacteroides* (Figure
102 1C and Supplementary Table 2). The ratio between *Firmicutes* and *Bacteroidetes* (F/B) was
103 8.5 ± 1.2 (mean \pm SEM) controls and 18.5 ± 2.6 for vitiligo patients (P<0.01).

104

105 *Significant microbial dissimilarity between swabs and biopsies*

106 To examine if there are differences in microbial composition and diversity in the skin of vitiligo
107 patients compared to healthy skin, we studied microbiota extracted from paired skin swabs
108 and skin biopsies from the same subject as well as collected samples from the patient's
109 lesional and non-lesional skin sites. We compared microbial communities α - and β -diversity
110 between swab or biopsy samples from control, lesional (L) and non-lesional (NL) sites (n=30
111 swab and n=30 biopsy). Observed OTUs and Shannon diversity index were higher in swabs
112 compared to biopsies (P<0.001 for both; Figure 2A), whereas Faith's PD was higher in biopsies
113 (P<0.001; Figure 2A), the latter suggesting higher phylogenetic richness in biopsies compared
114 to swabs. These results suggest richness and distribution of bacteria (α -diversity) differs in
115 relation to the sampling method. Furthermore, our results demonstrate distinct and significant
116 differences in β -diversity between biopsies and swabs (P<0.001, Figure 2B). We found higher
117 *Bifidobacterium* (with *B. bifidum* and *B. longum*), *Escherichia-Shigella*, *Parabacteroides* and
118 *Enterococcus* in biopsies compared to swabs, whereas *Staphylococcus*, *Paracoccus*, *Kocuria*,

119 *Micrococcus* and *Anaerococcus* were more abundant in the skin swabs ($p < 0.05$ for all
120 comparisons; Figure 2C). In the swabs, *Staphylococcus* was the most abundant genus making
121 up > 30% of all bacteria while in the biopsies, *Bifidobacterium* was the most common, making
122 up almost 60% of the total bacterial load. Taken together, these results demonstrate a marked
123 difference in the skin microbiome when analyzed using swab *versus* biopsy sampling and there
124 are several bacterial genera that correlates strongly and significantly with the sample collection
125 method or the depth of microbiota sampling.

126

127 *Depletion of Staphylococcus and enrichment of Proteobacteria in lesional swabs of vitiligo*
128 *patients*

129 Swab samples from NL and L vitiligo skin had a significantly higher α -diversity compared to
130 healthy control swabs ($P < 0.05$) (Figure 3A). There was no difference in α -diversity between
131 NL and L skin samples (Figure 3A). We found no significant differences in β -diversity between
132 healthy, NL and L skin swab samples. We observed decreased *Firmicutes* in L compared to
133 NL sites ($p < 0.01$) (Figure 3B and Supplementary Table 3); most likely due to decreased
134 *Staphylococcus* at this site ($p < 0.02$) (Figure 3C and Supplementary Table 4). Examining the
135 bacterial composition of swab microbiota at the genus level, we show that greater than half of
136 taxonomic assignments on skin surface belong to 5 major genera: *Staphylococcus*,
137 *Corynebacterium*, *Cutibacterium* (formerly *Propionibacterium*), *Kocuria* and *Paracoccus*
138 (Figure 3C). We found a trend for lower *Cutibacterium* in L compared to NL swabs ($p = 0.057$)
139 (Figure 3C) which may have important implications in vitiligo as the loss of *Cutibacterium*
140 diversity triggers activation of the innate immune system [11]. We have also seen trends for
141 increased *Proteobacteria* ($p = 0.08$) phylum in L compared to NL swabs (Figure 3B). As
142 *Proteobacteria* contains many well-known human pathogens and is related with disbalance
143 and inflammation [12], we investigated this phylum in more detail. We have shown a disease-
144 dependent increase in presence of *Gammaproteobacteria*, that is relative abundance in
145 L > NL > C swabs and disease-dependent decreased in *Alphaproteobacteria* (L < NL < C)
146 ($P = 0.046$) (Supplementary Figure 1A and Supplementary Table 5). Lesional skin enrichment

147 with *Gammaproteobacteria* has also been shown in the only other study to date in vitiligo
148 subjects [9]. We have shown trends for increased *Paracoccus* ($p=0.09$) and *Acinetobacter*
149 ($p=0.08$) in vitiligo swabs compared to control swabs (Supplementary Figure 1B). Differences
150 in *Haematobacter* were not statistically different due to patient variability.

151
152 *Biopsy microbiota in lesional skin have distinct composition and are associated with*
153 *mitochondrial damage*

154 In contrast to the swabs, microbial community β -diversity in L skin biopsies differed significantly
155 compared to NL skin biopsies or healthy controls ($p<0.001$) (Figure 4A) and had the most
156 distinct microbiota compared to all other groups (Supplementary Figure 2). We saw a decrease
157 in species richness and distribution (Shannon index, $P=0.006$) but increase in phylogenetic
158 diversity (Faith's PD, $P=0.003$) in biopsies from L compared to NL skin, whereas Shannon
159 index was higher in NL skin compared to controls ($P<0.01$) (Figure 4B). The taxa bar plots
160 suggest decreased *Actinobacteria* ($p=0.09$) and increased *Firmicutes* ($p=0.08$) in L compared
161 to NL or control biopsies (Figure 4C and Supplementary Table 6). In our cohort, the largest
162 difference was the increase in *Tenericutes* ($P<0.001$ for control versus NL and $P<0.02$ for NL
163 versus L) and mitochondrial DNA ($p<0.007$) exclusively in biopsies from 7/10 lesional skin
164 samples whereby 3 out of the 10 samples looked like NL skin (Figure 4C).

165
166 In the skin biopsies, greater than half of taxonomic assignments belong to 5 major *genera* (3
167 overlapping with the swabs): *Bifidobacterium*, *Escherichia-Shigella*, *Staphylococcus*,
168 *Cutibacterium* and *Parabacteroides* (Figure 4D and Supplementary Table 7). The heat map
169 illustrates the top 20 most differentially expressed bacterial taxa between the three groups at
170 the individual level (Supplementary Figure 3). Pair-wise analysis for differential abundance
171 between NL vitiligo biopsies and control biopsies have shown *Staphylococcus* and
172 *Cutibacterium* to be depleted in NL biopsies ($p=0.07$); the same two *genera* that were depleted
173 on the surface of L skin. In contrast, *Enterococcus*, *Mycoplasma*, *Veillonella*, *Intestinibacter*,
174 *Bacteroides*, *Escherichia-Shigella*, *Parabacteroides*, *Bifidobacterium*, and *Streptococcus* were

175 enriched at NL sites (all $p < 0.007$) (Supplementary Figure 3). Comparisons between L and NL
176 biopsies have shown L skin to be further enriched for *Streptococcus* as well as *Proteobacteria*
177 including *Gemella*, *Raistonia* and *Undibacterium* (all $p < 0.05$) with a large and specific increase
178 in *Mycoplasma* and Mitochondrial DNA (Figure 4D). In contrast, *Bifidobacterium*, *Escherichia-*
179 *Shigella*, *Parabacteroides* and *Enterococcus* were significantly depleted taxa in biopsies from
180 L compared to NL skin and compared to healthy biopsies (all $p < 0.05$). *Bifidobacterium* was
181 completely depleted in 7/10 L biopsies when compared to their matched NL sites in which
182 *Bifidobacterium* makes up almost 60% of the total bacterial genus (Figure 4D).

183
184 Finally, we further investigated the differences between the first 3 patients who didn't have an
185 increase in mitochondrial DNA in their skin biopsy to the remaining 7 patients who did.
186 Interestingly, these 3 patients had a similar microbiome to non-lesional samples, that is, low
187 abundance of *Tenericutes* and *Firmicutes* with predominant presence of *Actinobacteria* (Figure
188 4C). The difference between these 2 sub-groups of patients could not be explained by sex,
189 age, location of the biopsies, disease activity or disease duration. To further investigate if these
190 changes in the skin could activate the innate immune response, we measured the levels of
191 $IFN\gamma$ and chemokines CXCL9 and CXCL10 that we previously have shown to be increased
192 after stimulation of the innate cells of vitiligo patients by DAMPs or PAMPs [3]. We also
193 measured the levels of CXCL16 that is produced by keratinocytes and mediates CD8+ T cell
194 skin trafficking under oxidative stress in vitiligo patients [13]. The 7 patients with increased
195 mitochondrial DNA in lesional sites had a significantly increased levels of $IFN\gamma$, CXCL9 and
196 CXCL16 ($P < 0.05$) in their serum compared to the patients without elevated mitochondrial DNA
197 (Figure 4E). The corresponding levels of CXCL-10 in the serum were of borderline significance
198 ($P = 0.064$).

199

200

201 **DISCUSSION**

202 Gut, and to a lesser extent, skin dysbioses have been reported in many inflammatory and
203 autoimmune disorders. Surprisingly, microbiome studies in vitiligo remain limited. Here we
204 have shown, for the first time, dysbiosis in the gut and skin microbiota of vitiligo subjects
205 compared to controls. The most striking differences were detected in the deep dermis layer of
206 the lesional skin where enrichment of pathogenic *Tenericutes* bacteria and a loss of protective
207 *Bifidobacterium* were associated with mitochondrial damage at the same site as well as
208 increased stress and immune activation markers in their peripheral blood. We do acknowledge
209 the relative limited number of subjects analysed being a potential weakness of this study. It is
210 important to state that this was an invasive study requiring six samples *per* patient (2 skin
211 biopsies, 2 skin swabs, stool and a blood sample). Moreover, the group numbers were based
212 on recent human microbiome studies using the similar sequencing approach [9,14-17].

213
214 We detected reduced α -diversity (richness and distribution of bacterial species) in the stool of
215 vitiligo compared to controls with increased abundance of *Firmicutes* and reduced
216 *Bacteroidetes*. The ratio between *Firmicutes* and *Bacteroidetes* (F/B) was significantly higher
217 for vitiligo patients. A similar increase in the F/B ratio has previously been reported in other
218 autoimmune diseases such as type I diabetes, Grave's disease, lupus and multiple sclerosis
219 as well as autoimmune skin conditions including scleroderma and psoriasis [18]. Interestingly,
220 a protective effect of *Bacteroides* was recently reported in the gut of a mouse vitiligo model
221 and was associated with skin depigmentation of mice [10]. If the same protection holds true
222 for human vitiligo, reduction and/or lack of protective *Bacteroides* in the human gut may
223 contribute to disease onset or exacerbation. It is important to note that vitiligo depigmentation
224 is associated with better prognosis in melanoma patients [19] and interestingly, our stool
225 microbiota results in vitiligo patients (high F/B ratio) have striking similarities with good
226 responders in melanoma patients treated with anti-PD1 [20]. Together, these results
227 demonstrate differences in gut microbial composition between vitiligo and healthy controls and
228 may suggest a possible gut-skin axis in this disease.

229 Our results analyzing skin microbiota emphasize a marked difference in the skin microbiota
230 when analyzed using swab *versus* biopsy sampling suggesting that there are several bacterial
231 genera that correlates strongly and significantly with the sample collection method. Most of the
232 studies to date that assessed the microbiota in skin disorders have used only swab samples.
233 The unique aspect of our study is that we obtained stool, skin swab and skin biopsy samples
234 from the same individuals thereby reducing inter-patient variability and strengthening
235 robustness of our study. Our results are in agreement with those of Prast-Nielsen [7] and
236 emphasize the need for simultaneous collection of swab (surface) and biopsy (deep skin)
237 samples as biopsies are providing additional information which is critical in correct
238 interpretation of the data. Using swab samples, we found some albeit small differences and
239 trends in differential abundance of microbial composition between healthy and vitiligo skin
240 swabs; the largest differences seen in depletion of commensal *Staphylococcus* and
241 *Acinetobacter* and enrichment of pathogenic *Paracoccus* (*Proteobacteria*) in lesional skin.
242 *Staphylococcus epidermidis* is a known important symbiont in the skin which directly interacts
243 with cutaneous immune cells to regulate skin homeostasis [21]. *Staphylococcus* spp are also
244 known to colonise lesions in a number of dermatological diseases including atopic dermatitis
245 and presents propensity to form biofilms; adhesive surface-attached colonies that become
246 highly resistant to antibiotics and immune responses [22].

247
248 Current understanding of the skin microbiota is based on swab sampling the outermost layer
249 of the epidermis. Despite the invasive nature of biopsies, sampling dermal microbiota has
250 become critically important as the dermal community is less affected by external factors [8].
251 Our results give us, for the first time, a comprehensive profiling of the microbial species that
252 are depleted in full thickness subepidermal compartments of the vitiligo skin which may be
253 targeted for therapy. Thus, in contrast to the swabs, marked differences were found in microbial
254 community in lesional skin biopsies compared to non-lesional skin biopsies or healthy controls
255 with a decreased *Actinobacteria* and increased *Firmicutes*. Interestingly, the same imbalance
256 between *Actinobacteria* and *Firmicutes* in lesional *versus* non-lesional skin was found in the

257 only other study that assessed skin microbiota in vitiligo skin [9]. However, in our cohort, the
258 largest difference was the increase in *Tenericutes* and mitochondrial DNA in biopsies from
259 lesional skin. With such ‘black-and-white’ results even with the limited number of subjects, it is
260 tempting to speculate that *Tenericutes* may be used as a marker phylum for patients that may
261 benefit from a supplementation of probiotics or bacterial lysates with bifidobacteria in addition
262 to established treatment. Further analyses and interventional studies with bifidobacteria
263 supplementation are required to confirm this hypothesis.

264
265 The latest evidence in the literature emphasizes the interaction between mitochondria and
266 microbiota [23] ¹⁹. It has been recently shown that the mitochondrial genotype modulates both
267 reactive oxygen species (ROS) production and the species diversity of the gut microbiome
268 [24]. Interestingly, mitochondrial alterations with increased production of ROS have been
269 reported in vitiligo cells [25,26]. Our results are in accordance with these *in vitro* studies and
270 demonstrate potent mitochondrial damage in lesional skin of patients. As observed in the gut
271 of mice [24], α -diversity decreased in samples with high mitochondrial DNA. Modification of
272 the microbiome only in the biopsy samples having mitochondrial DNA strongly argues in favor
273 of microbiome modification induced by the mitochondrial stress. Interestingly, the genus that
274 was almost completely absent in the 7 patients with the mitochondrial DNA in the skin is
275 *Bifidobacterium* which is well-known to have protective effects and to decrease the activation
276 of innate immune cells [27]. Moreover, those 7 patients had also a significantly increased levels
277 of IFN γ , CXCL9, CXCL10 and CXCL16 in their serum compared to the patients without
278 elevated mitochondrial DNA. Thus, we can hypothesize that similarly to what has been shown
279 in the gut of mice [24], primitive mitochondrial stress in some vitiligo patients could be
280 responsible for the change in the skin microbiome. This skin dysbiosis could then trigger the
281 innate response through PAMPs and lead to the production of IFN γ and chemokines that can
282 be detected in the serum of these patients. Of course, this hypothesis needs to be confirmed

283 in larger number of patients and ideally metagenomics should be performed to characterize
284 the origin of mitochondrial DNA.

285 There are a number of unique aspects to this study. First and foremost it is its novelty. To our
286 knowledge, there are no data examining the role of microbiota in vitiligo skin compared to
287 healthy skin. Secondly, there are matched multiple samplings (swab, biopsy, stool, serum)
288 from each patient avoiding inter-patient variability and thereby allowing for robustness of the
289 data even with a relatively limited sample size. Our key data demonstrating differences
290 between skin swabs and skin biopsy microbiota and between lesional compared to non-
291 lesional or control skin are all highly significant ($P < 0.001$) suggesting important biological
292 differences between these sites. Thirdly, we have demonstrated the skin dysbiosis in vitiligo
293 patients is associated with profound mitochondrial damage and loss of protective bacteria at
294 the same site with heightened innate immune response in the blood of vitiligo patients
295 compared to healthy controls. These novel data not only describes vitiligo-specific cutaneous
296 and gut microbiota, but it also shows, for the first time in humans, a link between mitochondrial
297 alteration, microbiota and innate immunity. This opens up new avenues to explore in potential
298 treatment of vitiligo and other auto-immune disorders.

299 **MATERIALS AND METHODS**

300 *Biological samples*

301 Twenty (20) subjects were recruited for this study (Table 1). Ten vitiligo patients with stable
302 disease and 10 healthy patients were recruited from the Department of Dermatology, Archet 2
303 Hospital, CHU Nice, after informed, written consent was obtained. Exclusion criteria included
304 presence of other autoimmune diseases or *prior* treatment (phototherapy, topical or systemic
305 corticosteroids, systemic antibiotics and/or other immunosuppressive agents) for up to 3
306 months before skin sampling. The groups were matched for gender, age, and biopsy location.
307 All skin samples were taken from the dry locations (Table 1). Swab and biopsy samples were
308 collected at the same time for each patient. From each vitiligo patient, we obtained two 4-mm
309 skin punch biopsies (1 from lesional, L and 1 from non-lesional, NL site) and from each healthy
310 patient 1 skin biopsy of the same size. Skin swabs were taken at the same time from adjacent
311 skin area sampling 5cm x 5cm L and NL skin sites using sterile dry swabs (Copan Diagnostics)
312 and rinsed in 200 µl sterile 0.15 M NaCl and 0.1% Tween20 (v/v). The same morning, stool
313 samples as well as 10 mL of blood was also collected from all subjects. Serum was obtained
314 from the blood following Ficoll gradient centrifugation (Lymphoprep®, Euromedex, France). All
315 biological samples (n=60 from vitiligo patients and n=40 from healthy controls) were stored at
316 -80° C until analysis. The study was approved by the National Ethics Committee (N14.028)
317 and was carried out in accordance with The Code of Ethics of the World Medical Association
318 (Declaration of Helsinki).

319

320 *DNA isolation from stool samples*

321 Eighty to 120 mg of frozen stool was transferred to Precellys soil grinding SK38 lysing tubes
322 (Bertin Technologies, Montigny-le-Bretonneux, France) and one volume of warm (37° C) lysis
323 buffer [4% (w/v) SDS, 50 mM TrisHCl pH 8.0, 500 mM NaCl, 50 mM EDTA] was added.
324 Samples were homogenized for 10 mins at room temperature using a Vortex adapter.
325 Lysozyme (Sigma Aldrich Chemie GmbH, Germany; final concentration 6.25 mg/ml) was
326 added and samples were incubated at 37° C for 30 min, then transferred to 80° C heating block

327 and incubated for 15 mins by inverting every 5 mins. Samples were then centrifuged at 4° C
328 20,000g for 5 mins and supernatants were collected; proteinase K (Roche Diagnostics GmbH,
329 Germany) was added (final concentration 0.4 mg/ml) and the samples were incubated on a
330 heating block at 70° C for 10 mins. After incubation, 10 M NH₄OAc (final concentration 2 M)
331 was added and samples were incubated on ice for 5 mins, then centrifuged at 4° C 20,000g
332 for 10 mins. Supernatants were collected and an equal volume of cold isopropanol was added.
333 The samples were stored on ice for 30 mins and thereafter centrifuged at 4° C 20,000g for 20
334 mins. Pellets were washed 2-3 times with cold 70% ethanol, dried and dissolved overnight in
335 commercial Tris-EDTA buffer (1xTE). The following day, the DNA concentrations were
336 measured using Qubit dsDNA Broad Range Assay kit (Thermo Fisher Scientific Inc., USA) on
337 Qubit 3.0 fluorometer (Thermo Fisher Scientific Inc., USA). RNase (Thermo Scientific,
338 Lithuania) at final concentration of 1 µg/µl.

339

340 *DNA isolation from skin samples*

341 Bacterial DNA was extracted from skin biopsies and swabs using QIAamp® DNA Microbiome
342 Kit (Cat. No. 51704) (QIAGEN GmbH, 40724 Hilden, Germany). We followed manufacturer's
343 protocol with a single modification. After addition of Proteinase K the second time, samples
344 were incubated overnight on a heating block at 56° C. After eluting DNA, the concentrations
345 were measured using Qubit™ 1X dsDNA HS Assay Kit (Life Technologies Corporation, Oregon
346 97402, USA) on Qubit 4.0 fluorometer (Thermo Fisher Scientific Inc., USA).

347

348 *16S rRNA Gene Library Preparation and Amplicon Sequencing*

349 The sequencing library was prepared according to Earth Microbiome Project's Protocol [28]
350 with the following modifications. The fused primers were modified to contain barcode sequence
351 on both forward (341F) and reverse (805R) primers and selected to target the V3-V4 region
352 instead of the V4 region. Sequences of fused primers are provided as Supplementary Table
353 8. The PCR reactions for library preparation were carried out in triplicates as follows: 20 ng of
354 template DNA was mixed with 5PRIME HotMasterMix (Quantabio, USA) consisting of: 1U Taq

355 polymerase, 45 nM Cl, 2.5 mM Mg²⁺, 0.2 mM of each dNTP, 0.2 μM of each primer (Eurofins
356 Genomics, Germany) and 0.64 ng bovine serum albumin (BSA) in a final volume of 25 μl *per*
357 reaction. The PCR conditions were: 90° C for 15s and 94° C for 3 mins followed by 35 cycles
358 of 94° C for 45s, 50° C for 1 min and 72° C for 1.5 mins, after which a final elongation step at
359 72° C for 10 mins was performed. The triplicates were pooled and visualized on 1% agarose
360 gel to estimate the size of the amplicons. DNA concentrations of the amplicons were measured
361 as described in the section above. Every PCR run included a negative (water) and a positive
362 (MOCK community sample) control. The following reagent was obtained through the NIH
363 Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH as part of
364 the Human Microbiome Project: Genomic DNA from Microbial Mock Community B (Even, Low
365 Concentration), v5.1L, for 16S RNA Gene Sequencing, HM-782D. Libraries were then pooled
366 in equimolar concentrations and the amplicon pool was purified according to protocol using
367 AMPure XP beads (Beckman Coulter, USA). Prior to amplicon sequencing the amplicon pool
368 was diluted in 10 mM Tris-HCl (pH 8.5) to a final concentration of 5 nM. Following the Illumina
369 recommendations, the amplicon pool was denatured using an equal amount of 0.2 M NaOH
370 (BioUltra) (Sigma Aldrich Chemie GmbH, Germany) and further diluted to 12 pM in
371 hybridization buffer (HT1 buffer included in the Reagents Kit v3, Illumina, USA). The pool was
372 finally spiked with 5% denatured PhiX control library (Illumina, USA). The sequencing was
373 performed using the MiSeq sequencing platform with the Reagents Kit v3, 600 cycles (Illumina,
374 USA).

375

376 *Microbiome Analyses: Composition, Diversity and Discovery of Metagenomic Biomarkers*

377 The composition and diversity of the gut microbiome were assessed using QIIME2 [29].
378 Initially, read-pairs were demultiplexed using deML [30] before sequences were quality filtered
379 and denoised using DADA2 [31]. For stool samples, total sequencing yield was 1,595,147
380 reads with median of 74,594 (n=21). For skin samples 7,499,237 reads was a total yield
381 distributed among 73 samples, with median of 96,497. Raw sequence data were
382 demultiplexed and quality filtered using the q2-demux plugin followed by denoising with

383 DADA2 [31]. All amplicon sequence variants (ASVs) were aligned with mafft [32] and used to
384 construct a phylogeny with fasttree2 [33]. α -diversity metrics (observed OTUs, Shannon index
385 and Faith's Phylogenetic Diversity [34]) and β -diversity metrics (unweighted UniFrac) [35] and
386 also Principle Coordinate Analysis [PCoA]) were estimated after samples were rarefied to 1000
387 sequences *per* sample. Shannon index accounts for both richness (number of species) and
388 distribution (how evenly the species are distributed) while Faith's PD pertains more to
389 phylogenetic diversity in a sample. β -diversity measures differences in microbial composition
390 between different samples. Taxonomy was assigned to ASVs using the q2-feature-classifier
391 [36] classify-sklearn naïve Bayes taxonomy classifier against the SILVA full-length 99% OTUs
392 reference sequences [37].

393

394 *ELISA*

395 IFN γ , CXCL9 and CXCL10 were measured from the serum using commercially available
396 ELISA kits (Peprotech, NJ, USA) while CXCL16 ELISA was purchased from R&D Systems
397 (Minnesota, USA).

398

399 *Statistical analyses*

400 Differences in α - and β -diversity between groups were calculated using Kruskal-Wallis test (p
401 value is FDR adjusted) and PERMANOVA (number of permutations=999), respectively. We
402 have used ANCOM [38] to investigate differentially abundant bacteria between the groups
403 (P<0.05, FDR adjusted for the analysis). Additionally, non-parametric independent sample t-
404 test (between controls and vitiligo subjects) and paired sample t-test (between lesional and
405 non-lesional samples) were used. For all tests P<0.05 was considered significant and P
406 between 0.06 and 0.1 a trend.

407

408

409

410 **ACKNOWLEDGEMENTS:**

411 We would like to thank Mona Svensson and Carina Lagerqvist for laboratory work, Emelie
412 Näslund Salomonsson for assistance with Illumina MiSeq run, as well as Sonia Amroune and
413 Raja Bahroumi for their assistance in clinic with patient recruitment. This work was supported
414 by the Institut National de la Santé et de la Recherche Médicale (INSERM).

415

416 **AUTHOR CONTRIBUTIONS:**

417 HB was involved in sample collection and their processing, data analysis and interpretation,
418 as well as manuscript writing and construction of Figures. KSS along with CEW optimized the
419 protocol for extraction of DNA from skin biopsies. KSS performed DNA extractions, 16S
420 sequencing, statistical analysis and construction of Figures. KSS, SR and CEW provided
421 intellectual input, expertise and feedback on manuscript draft. AK performed all swab and
422 biopsy collections from vitiligo patients. TP was involved in patient recruitment. MKT performed
423 all the ELISA measurements. MKT and TP conceived the experiments, obtained financial
424 support, supervised the study, were involved in data interpretation and together wrote the
425 manuscript. All authors have read and approved the final version of the paper.

426

427 **CONFLICT OF INTEREST:**

428 The authors have no conflict of interest. This work was supported by a grant from ISISPharma.
429 The funding source had no involvement in study design, collection, analysis or interpretation
430 of the data or in writing of this manuscript.

431

432 **DATA AVAILABILITY:**

433 Sequence data have been deposited to the Sequence Read Archive (SRA) under accession
434 number PRJNA639425. All other data that support the findings of this study are available from
435 the corresponding authors upon reasonable request.

436

437 **REFERENCES**

438

- 439 1. Roberts GHL, Santorico SA, Spritz RA. The genetic architecture of vitiligo. *Pigment*
440 *Cell Melanoma Res.* 2020; 33:8-15.
- 441 2. Jin Y, Santorico SA, Spritz RA. Pediatric to Adult Shift in Vitiligo Onset Suggests Altered
442 Environmental Triggering. *J Invest Dermatol.* 2020; 140:241-243.
- 443 3. Tulic MK, Cevazza E, Cheli Y, Jacquel A, Luci C, Cardot-Leccia N et al., Innate
444 lymphocyte-induced CXCR3B-mediated melanocyte apoptosis is a potential initiator of
445 T-cell autoreactivity in vitiligo. *Nature Comm.* 2019; 10:2178.
- 446 4. O'Neill AM, Gallo RL. Host-microbiome interactions and recent progress into
447 understanding the biology of acne vulgaris. *Microbiome.* 2018; 6:177.
- 448 5. Stehlikova Z, Kostovcik M, Kostovcikova K, Kverka M, Juzlova K, Rob F et al. Dysbiosis
449 of Skin Microbiota in Psoriatic Patients: Co-occurrence of Fungal and Bacterial
450 Communities. *Front Microbiol.* 2019; 10:438.
- 451 6. Williams MR, Gallo RL. Evidence that Human Skin Microbiome Dysbiosis Promotes
452 Atopic Dermatitis. *J Invest Dermatol.* 2017; 137:2460-2461.
- 453 7. Prast-Nielsen S, Tobin AM, Adamzik K, Powels A, Hugerth LW, Sweeney C et al.
454 Investigation of the skin microbiome: swabs vs. biopsies. *B J Dermatol.* 2019; 181:572-
455 579.
- 456 8. Bay L, Barnes CJ, Fritz BG, Thorsen J, Restrup MEM, Rasmussen L et al. Universal
457 Dermal Microbiome in Human Skin. *mBio* 2020; Feb11:e02945-19.
- 458 9. Ganju P, Nagpal S, Mohammed MH, Nishal Kumar P, Pandey R, Natarajan VT et al.
459 Microbial community profiling shows dysbiosis in the lesional skin of Vitiligo subjects.
460 *Sci Rep.* 2016; 6:18761.
- 461 10. Dellacecca ER, Cosgrove C, Mukhatayev Z, Akhtar S, Engelhard VH, Rademaker AW
462 et al. Antibiotics Drive Microbial Imbalance and Vitiligo Development in Mice. *J Invest*
463 *Dermatol.* 2020 Mar;140(3): 676-687.e6. doi: 10.1016/j.jid.2019.08.435.

- 464 11. Dagnelie MA, Corvec S, Saint-Jean M, Nguyen JM, Khammari A, Dreno B.
465 Cutibacterium canes phylotypes diversity loss: a trigger for skin inflammatory process.
466 J Eur Acad Dermatol Venereol. 2019 Dec;33(12):2340-2348. doi: 10.1111/jdv.15795.
467 Epub 2019 Aug 20.
- 468 12. Rizzatti G, Lopetuso LR, Gibiino G, Binda C, Gasbarrini A. Proteobacteria: A Common
469 Factor in Human Diseases. Biomed Res Int. 2017;2017:9351507. doi:
470 10.1155/2017/9351507. Epub 2017 Nov 2.
- 471 13. Li S, Zhu G, Yang Y, Jian Z, Guo S, Dai W, et al. Oxidative stress drives CD8(+) T-cell
472 skin trafficking in patients with vitiligo through CXCL16 upregulation by activating the
473 unfolded protein response in keratinocytes. J Allergy Clin Immunol. 2017
474 Jul;140(1):177-189.e9. doi: 10.1016/j.jaci.2016.10.013. Epub 2016 Nov 5.
- 475 14. Nakatsuji T, Chiang HI, Jiang SB, Nagarajan H, Zengler K, Gallo RL. The microbiome
476 extends to subepidermal compartments of normal skin. Nature Comm. 2013; 4:1431.
- 477 15. Jakobsson HE, Abrahamsson TR, Jenmalm MC, Harris K, Quince C, Jernberg C et al.
478 Decreased gut microbiota diversity, delayed Bacteroidetes colonisation and reduced
479 Th1 responses in infants delivered by caesarean section. Gut. 2014; 63:559-566.
- 480 16. Fadlallah J, Sterlin D, Fieschi C, Parizot C, Dorgham K, Kafsi HE et al. Synergistic
481 convergence of microbiota-specific systemic IgG and secretory IgA. J Allergy Clin
482 Immuno. 2019;143:1575-1585.
- 483 17. Baurecht H, Ruhlemann MC, Rodrigues E, Thielking F, Harder I, Erkens AS et al.
484 Epidermal lipid composition, barrier integrity, and eczematous inflammation are
485 associated with skin microbiome configuration. J Allergy Clin Immunol. 2018;
486 141:1668-1676.
- 487 18. Opazo MC, Ortega-Rocha EM, Coronado-Arrazola I, Bonifaz LC, Boudin H, Neunlist
488 M et al. Intestinal microbiota influences non-intestinal related auto-immune diseases.
489 Front Microbiol. 2018 Mar 12;9:432. doi: 10.3389/fmicb.2018.00432. eCollection 2018.
- 490 19. Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI et al.
491 Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving

- 492 immunotherapy and its association with survival: a systematic review and meta-
493 analysis. *J Clin Oncol.* 2015; 33:773-781.
- 494 20. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al.
495 Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma
496 patients. *Science.* 2018; 359:97-103.
- 497 21. Leonel C, Sena IFG, Silva WN, Prazeres P, Fernandes GR, Mancha Agresti P et al.
498 *Staphylococcus epidermidis* role in the skin microenvironment. *J Cell Mol Med.* 2019;
499 23:5949-5955.
- 500 22. Gonzalez T, Biagini Myers JM, Herr AB, Khurana Hershey GK. *Staphylococcal Biofilms*
501 *in Atopic Dermatitis.* *Curr Allergy Asthma Rep.* 2017; 17(12):81.
- 502 23. Saint-Georges-Chaumet Y, Edeas M. Microbiota-mitochondria inter-talk: consequence
503 for microbiota-host interaction. *Pathog Dis.* 2016; 74:ftv096.
- 504 24. Yardeni T, Tanes CE, Bittinger K, Mattei LM, Schaefer PM, Singh LN et al. Host
505 mitochondria influence gut microbiome diversity: A role for ROS. *Sci Signal.* 2019;
506 12(588):eaaw3159. doi: 10.1126/scisignal.aaw3159.
- 507 25. Sahoo A, Lee B, Boniface K, Seneschal J, Sahoo SK, Seki T et al. MicroRNA-211
508 Regulates Oxidative Phosphorylation and Energy Metabolism in Human Vitiligo. *J*
509 *Invest Dermatol.* 2017; 137:1965-1974.
- 510 26. Dell'Anna ML, Ottaviani M, Kovacs D, Mirabilii S, Brown DA, Cota C et al. Energetic
511 mitochondrial failing in vitiligo and possible rescue by cardiolipin. *Sci Rep.* 2017;
512 7:13663.
- 513 27. Iacob S, Iacob DG. Infectious Threats, the Intestinal Barrier, and Its Trojan Horse:
514 Dysbiosis. *Front Microbiol.* 2019; 10:1676.
- 515 28. Gilbert JA, Jansson JK, Knight RI. The earth microbiome project: successes and
516 aspirations. *BMC Biol.* 2014 Aug 22;12:69. doi: 10.1186/s12915-014-0069-1.
- 517 29. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA et al.
518 Reproducible, interactive, scalable and extensible microbiome data science using
519 QIIME 2. *Nat Biotechnol.* 2019; 37:852-857.

- 520 30. Renaud G, Stenzel U, Maricic T, Wiebe V, Kelso J. deML: robust demultiplexing of
521 Illumina sequences using a likelihood-based approach. *Bioinformatics*. 2015; 31:770-
522 772.
- 523 31. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2:
524 High-resolution sample inference from Illumina amplicon data. *Nat Methods*. 2016;
525 13:581-583.
- 526 32. Katoh K, Misawa K, Kuma K, Miyata T. MAFFT: a novel method for rapid multiple
527 sequence alignment based on fast Fourier transform. *Nucleic Acids Res*. 2002;
528 30:3059-3066.
- 529 33. Price MN, Dehal PS, Arkin AP. FastTree 2--approximately maximum-likelihood trees
530 for large alignments. *PLoS One*. 2010; 5:e9490.
- 531 34. Faith DP. The role of the phylogenetic diversity measure, PD, in bio-informatics: getting
532 the definition right. *Evol Bioinform Online*. 2007; 2:277-283.
- 533 35. Lozupone C, Knight R. UniFrac: a new phylogenetic method for comparing microbial
534 communities. *Appl Environ Microbiol*. 2005; 71:8228-8235.
- 535 36. Bokulich NA, Kaehler BD, Rideout JR, Dillon M, Bolyen E, Knight R et al. Optimizing
536 taxonomic classification of marker-gene amplicon sequences with QIIME 2's q2-
537 feature-classifier plugin. *Microbiome*. 2018; 6:90.
- 538 37. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P et al. The SILVA
539 ribosomal RNA gene database project: improved data processing and web-based
540 tools. *Nucleic Acids Res*. 2013; 41:D590-596.
- 541 38. Mandal S, Van Treuren W, White RA, Eggesbo M, Knight R, Peddada SD. Analysis of
542 composition of microbiomes: a novel method for studying microbial composition.
543 *Microb Ecol Health Dis*. 2015; 26:27663.
- 544
- 545
- 546
- 547


548 **TABLE 1. Patient Characteristics**

549

Characteristics	Healthy controls	Vitiligo
<i>Subjects (n)</i>	10	10
<i>Age (years), mean (SE)</i>	60.2 (2.8)	51.5 (3.9)
<i>Gender (male/female)</i>	4/6	3/7
<i>Mean disease duration (years)</i>	-	3.2 (1.4 - 22)
<i>Family history (%)</i>	-	2 (20%)
<i>Location of biopsy (n)</i>	Shoulder (5), forearm (3), leg (1), ankle (1)	Forearm (5), leg (4), ankle (1)

550

551



552


553 **Figure 1** Reduced α -diversity and increased Firmicutes/Bacteroides ratio in the gut microbiota
 554 of vitiligo subjects

555 **(A)** Boxplots illustrating the comparison of different measures of α -diversity between healthy
 556 (n=10) and vitiligo (n=10) stool samples. **(B)** Bacterial composition and diversity expressed as
 557 a percentage of relative abundance between the two groups at the phylum and **(C)** genus
 558 levels. Individual subjects are shown as taxa bars (above) and grouped data as pie charts
 559 (below). A complete list of OTUs is shown in Supplementary Table 1 and Table 2.

560

561

562



563

564

565 **Figure 2** Difference in bacterial diversity and bacterial composition between swabs and
 566 biopsies due to sampling method

567 (A) Boxplots illustrating the comparison of different measures of α -diversity in paired samples
 568 of skin biopsies (n=30) and skin swabs (n=30). (B) PCoA plot representing β -diversity in
 569 biopsies (red circles) and swabs (blue circles) ($p < 0.001$). (C) Demonstrates sampling-method
 570 related differential bacterial abundance where bacteria enriched at each site is denoted and
 571 given as a percentage of total genus.

572


573

574

575

576

577




578

579

580 **Figure 3** Higher α -diversity, depletion of *Staphylococcus* and enrichment of *Proteobacteria* in
 581 *lesional swabs of vitiligo patients*

582 **(A)** Boxplots illustrating the comparison of different measures of α -diversity in skin swabs taken
 583 from non-lesional (NL) and lesional (L) regions of the skin from vitiligo patients (n=10)
 584 compared to skin swabs taken from healthy controls (n=10). **(B)** Bacterial composition and
 585 diversity (expressed as percentage of relative abundance) between the groups are shown at
 586 the phylum and **(C)** genus levels with individual taxa data shown above and grouped average
 587 data as pie charts below. A complete list of OTUs is shown in Supplementary Table 3 and
 588 Table 4.

589



590

591

592 **Figure 4** Lesional biopsies from vitiligo patients have distinct microbiota and are associated

593 with changes in bacterial diversity, mitochondrial damage and activation of the innate immune

594 system

595 **(A)** PCoA plot representing beta diversity between the different groups illustrating biopsies

596 from the lesional zone of vitiligo patients (red circles) to be significantly different from all other

597 samples ($P < 0.001$).

598 **(B)** Boxplots illustrating the comparison of different measures of α -diversity in skin biopsies taken from non-lesional (NL) and lesional (L) regions of the skin from

599 vitiligo patients (n=10) compared to skin biopsies taken from healthy controls (n=10). **(C)**
600 Bacterial composition and diversity (expressed as percentage of relative abundance) between
601 the two groups at the phylum and genus **(D)** level. Individual subjects are shown as taxa bar
602 plots (above) and grouped data as pie charts (below). A complete list of OTUs is shown in
603 Supplementary Table 6 and Table 7. **(E)** Measurements of innate (IFN γ , CXCL9, CXCL10) and
604 stress marker (CXCL16) proteins in the serum of vitiligo patients with elevated mitochondrial
605 signature (patients 4-10 in C) compared to vitiligo patients without increased mitochondrial
606 signature (patients 1-3).

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626